


## Claims

What is claimed is:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof,



wherein

A is a saturated 3-6 membered carbocyclic ring, optionally substituted by one or more C<sub>1-4</sub>alkyl group;

B is a saturated 4-6 membered heterocyclic ring, in which one or two carbon atoms are optionally replaced by an heteroatom selected from Nitrogen and Oxygen; such ring is optionally substituted at the carbon atoms or at a different Nitrogen atom, by one or more C<sub>1-4</sub>alkyl group;

G is phenyl or pyridyl optionally substituted by 1, 2, 3, 4 or 5 substituents independently selected from the group consisting of: halogen, cyano, hydroxyl, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, C(=O)NH<sub>2</sub> and C(=O)(O)<sub>z</sub>R<sub>3</sub>;

W is S, SO<sub>2</sub>, O, CHR<sub>2</sub> or NR<sub>3</sub>;

n is 0 or 1;

m is 1 or 2;

p is 1 or 2;

z is each independently 0 or 1;



R is hydrogen or C<sub>1-4</sub>alkyl; C<sub>1-4</sub>alkoxy;

R<sub>1</sub> is each independently hydrogen or F, C<sub>1-4</sub>alkyl; OH, C<sub>1-4</sub>alkoxy;

R<sub>2</sub> is each independently hydrogen or F, C<sub>1-4</sub>alkyl; OH, C<sub>1-4</sub>alkoxy;

R<sub>3</sub> is each independently hydrogen or C<sub>1-4</sub>alkyl;




- R<sub>4</sub> is each independently hydrogen or C<sub>1-4</sub>alkyl; or -C(=O)C<sub>1-4</sub>alkyl; -C(=O)C<sub>1-4</sub>alkoxyC<sub>1-4</sub>alkyl; -C(=O)C<sub>3-6</sub>cycloalkyl;  
 R<sub>5</sub> is each independently hydrogen or C<sub>1-4</sub>alkyl;  
 R<sub>6</sub> is each independently hydrogen or C<sub>1-4</sub>alkyl;  
 5 R<sub>7</sub> is each independently halogen, C<sub>1-4</sub>alkyl; OH, C<sub>1-4</sub>alkoxy;  
  
 G<sub>1</sub> is a 5-6-membered heteroaromatic group containing at least one ring nitrogen; which is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, hydroxyl, amino, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkoxy, SF<sub>5</sub>, C(=O)NH<sub>2</sub> and C(=O)(O)<sub>2</sub>R<sub>3</sub>;  
 10 Y is phenyl or a moiety selected from the group consisting of: 5-6 membered heteroaromatic group, a 8-11 membered heteroaromatic group, a saturated mono 3-7 membered carbocyclic group and a 8-11 membered bicyclic carbocyclic group, and for any of such groups one or more ring carbons is optionally replaced by N(R<sub>4</sub>)<sub>z</sub>, O, S; any of which groups is optionally substituted by 1, 2 or 3  
 15 substituents selected from: halogen, cyano, hydroxyl, C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, haloC<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkoxy, oxo, -NHC(=O)C<sub>1-4</sub>alkyl, -NR<sub>5</sub>R<sub>6</sub>, SF<sub>5</sub>, -(CH<sub>2</sub>)<sub>z</sub>C(=O)NR<sub>5</sub>R<sub>6</sub>, -C(=O)(O)<sub>2</sub>R<sub>3</sub>, -C<sub>1-4</sub>alkylCN, -SO<sub>2</sub>NR<sub>5</sub>R<sub>6</sub>, Y' or OY';  
 Y' is phenyl, or a 5-6-membered heteroaromatic group optionally substituted by 1 or 2 R<sub>7</sub> groups; provided that Y, Y' and G<sub>1</sub> are not simultaneously phenyl.  
 20  
 2. A compound or a pharmaceutically acceptable salt thereof, according to claim 1, wherein A and B are selected from the following:



and wherein G, G<sub>1</sub>, W, Y, n, m, p, z, R, R<sub>1</sub> and R<sub>2</sub> are as defined in claim 1.


3. A compound or a pharmaceutically acceptable salt thereof, according to claim 1, wherein A and B are selected from the following:

5





and wherein G, G<sub>1</sub>, W, Y, n, m, p, z, R, R<sub>1</sub> and R<sub>2</sub> are as defined in claim 1.

4. A compound or a pharmaceutically acceptable salt thereof, according to claim 1, of formula (IIA)



5 16. A compound of claim 1 having the formula:





17. A compound according to any one of claims 1-16 for use as a medicament.
18. A pharmaceutical composition comprising a compound as claimed in any one of  
5 claims 1-16 and a pharmaceutically acceptable carrier.
19. Use of the compound of any of claims 1 to 17 in the manufacture of a medicament for treating psychosis or a psychotic condition.
20. Use of the compound of any of claims 1 to 17 in the manufacture of a medicament for treating substance abuse.
- 10 21. Use of the compound of any of claims 1 to 17 in the manufacture of a medicament for treating schizophrenia.
22. Use of the pharmaceutical composition of claim 18 in the manufacture of a medicament for treating a psychotic condition.
23. Use of the pharmaceutical composition of claim 18 in the manufacture of a  
15 medicament for treating schizophrenia.
24. Use of the pharmaceutical composition of claim 18 in the manufacture of a medicament for treating substance abuse.
25. Compound according to any one of claims 1-16, or a pharmaceutical composition according to claim 18 for use in treating psychosis or a psychotic condition.

26. Compound according to any one of claims 1-16, or a pharmaceutical composition according to claim 18 for use in treating substance abuse.

27. Compound according to any one of claims 1-16, or a pharmaceutical composition according to claim 18 for use in treating schizophrenia.